Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis
NCT ID: NCT02907749
Last Updated: 2020-08-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
96 participants
INTERVENTIONAL
2018-01-01
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.
NCT07108075
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
NCT06082843
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
NCT05161481
Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS
NCT02925975
Natural History of Noncirrhotic Portal Hypertension
NCT02417740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Carvedilol
Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
Spironolactone and carvedilol
Patients are treated with carvedilol in combination with spironolactone.
Spironolactone and carvedilol
1. Carvedilol starts at 6.25mg/d and increases to 12.5mg/d in next week as a maintainence dose
2. Spironolactone is added after carvedilol being tolerated, which starts with 20mg/d and increases to 40mg/d as a maintainence dose
Carvedilol
Patients are treated with carvedilol only.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone and carvedilol
Patients are treated with carvedilol in combination with spironolactone.
Carvedilol
Patients are treated with carvedilol only.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Severe cardiopulmonary or renal insufficiency
* Chronic alcohol abuse
* Can't tolerate side effects of oral carvedilol or spironolactone
* History of variceal bleeding
* Malignancy
* Portal vein thrombosis
* History of partial splenic embolization or splenectomy
* Moderate or tense ascites
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changqing Yang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Changqing Yang
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jing Li, M.D.
Role: STUDY_DIRECTOR
Shanghai Tongji Hospital, Tongji University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Tongji Hospital, Tongji University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Yang-20160905
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.